Global R&D Pipeline
My Favorite
Hot Targets:
Mesothelin
Back
Total number of drugs
193
Phase II and later clinical stages
3.1%
Involving companies
170
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CB-693 | CB-693 | Bispecific antibody | - | 4-1BB agonists MSLN modulators | Crescendo Biologics Ltd. | Crescendo Biologics Ltd. | Discovery | - | - | - | - | - | - | - | - | - | CB-693 | - | - | detail > | |
| Misitatug | Misitatug | Monoclonal antibody | Neoplasms | MSLN inhibitors | RemeGen Co., Ltd. | RemeGen Co., Ltd. | Discovery | Discovery | - | - | - | - | - | - | - | - | Misitatug | - | - | detail > | |
| WO2023060157 | WO2023060157 | Bispecific antibody | Neoplasms | - | Link Immunotherapeutics, Inc. | Link Immunotherapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | WO2023060157 | - | - | detail > | |
| CN117843793 | CN117843793 | Monoclonal antibody | Neoplasms | - | 深圳真实生物医药科技有限公司 | 深圳真实生物医药科技有限公司 | Discovery | - | - | - | - | - | - | - | - | - | CN117843793 | - | - | detail > | |
| Anti-EGFR/MSLN/CD3 Trispecific antibody(GC Biopharma) | Anti-EGFR/MSLN/CD3 Trispecific antibody(GC Biopharma) | Trispecific antibody | Neoplasms | CD3 modulators EGFR antagonists MSLN inhibitors | GC Biopharma Corp. | GC Biopharma Corp. | Discovery | - | - | - | - | - | - | - | - | - | Anti-EGFR/MSLN/CD3 Trispecific antibody(GC Biopharma) | - | - | detail > | |
| CN116925226 | CN116925226 | Monoclonal antibody | Neoplasms | - | Shanghai Dino Xin'an Biotechnology Co., Ltd. | Shanghai Dino Xin'an Biotechnology Co., Ltd. | Discovery | - | - | - | - | - | - | - | - | - | CN116925226 | - | - | detail > | |
| WO2024259305 | WO2024259305 | Nanobody | Neoplasms | - | The Broad Institute, Inc.The General Hospital Corp.Dana-Farber Cancer Institute, Inc. | The Broad Institute, Inc.Dana-Farber Cancer Institute, Inc.The General Hospital Corp. | Discovery | - | - | - | - | - | - | - | - | - | WO2024259305 | - | - | detail > | |
| WO2024153172 | WO2024153172 | CAR-NK | Neoplasms Infectious Diseases | - | Institute of Zoology Chinese Academy of Science北京干细胞与再生医学研究院 | 北京干细胞与再生医学研究院Institute of Zoology Chinese Academy of Science | Discovery | - | - | - | - | - | - | - | - | - | WO2024153172 | - | - | detail > | |
| Anti-mesothelin HiTs(Adaptimmune) | Anti-mesothelin HiTs(Adaptimmune) | T-lymphocyte cell therapy | Neoplasms | MSLN inhibitors | Adaptimmune Ltd. | Adaptimmune Ltd. | Discovery | - | - | - | - | - | - | - | - | - | Anti-mesothelin HiTs(Adaptimmune) | - | - | detail > | |
| CN118307677 | CN118307677 | Monoclonal antibody | Neoplasms | - | Institute of Medicinal Biotechnology Academy of Medical Scien | Institute of Medicinal Biotechnology Academy of Medical Scien | Discovery | - | - | - | - | - | - | - | - | - | CN118307677 | - | - | detail > |
Total 193 data
1
2
3
4
5
6
...
19
20
